197
0 Kommentare
Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy - Seite 4
Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be
identified by words such as “potential,” “can,” “will,” “may,” “could,” “anticipated,” “believe,” “committed,” “investigational,” “pipeline,” “to develop,” “intends,” “to initiate,” “anticipated,”
“advances,” “bringing forward,” “to lead,” “development,” “ongoing,” “to address,” “intends,” “to enable,” or similar terms, or by express or implied discussions regarding potential marketing
approvals or labeling for remestemcel-L, or regarding potential future revenues from remestemcel-L; or regarding the worldwide license and collaboration agreement to develop, commercialize and
manufacture remestemcel-L. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and
are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual
results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the transaction described in this press release will be completed in the expected
time frame, or at all. Neither is there any guarantee that the expected benefits and synergies from such transaction will be achieved in the expected timeframe, or at all. Nor can there be any
guarantee that remestemcel-L will be submitted or approved for sale in any market, or at any particular time. Neither can there be any guarantee that remestemcel-L will be commercially successful
in the future. In particular, our expectations regarding the transaction described in this press release and remestemcel-L could be affected by, among other things, the expiration or termination of
the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and satisfaction of certain other closing conditions; the uncertainties inherent in research and development, including
clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment,
including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual
property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate
pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information
technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this
press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or
otherwise.